Selina M. Luger, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, shares some insights into the importance of dose intensity and how to select the most appropriate induction therapy for patients with acute myeloid leukemia (AML). Prof. Luger highlights how age, karyotype and mutations play a key role in determining which patients need dose intensive therapy versus reduced intensity therapy. Following this, Prof. Luger discusses several trials which have indicated that a higher dose of daunorubicin is beneficial for younger patients with AML, and then goes on to discuss the benefit of reduced intensity therapy for older patients. To conclude, Prof. Luger emphasizes the need for more trials evaluating dose intensive therapy in patients between the ages of 60-70, to allow further improvement to standard therapy for AML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.